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NATurE CEll BiOlOGy transcriptase PCR (qRT-PCR) assays and immunoblotting (IB) showed that TMEM9 expression in CRC was much higher than in other tissues (Fig. 1d ). Immunohistochemistry (IHC) of tumour microarrays (TMAs) validated the upregulation of TMEM9 in CRC patient samples, whereas it was barely expressed in normal intestinal crypts (Fig. 1e,f) . Given the pivotal roles of Wnt Oncomine analysis of TMEM9 expression in human cancers (www.oncomine.org). 10% gene rank; P < 0.0001; fold change > 2; compared with normal cells. c, High expression of TMEM9 in CRC. Two IECs and nine CRC cells were collected for IB and qRT-PCR. Tubulin served as a loading control, and TMEM9 expression was normalized by HPRT1. n = 3 independent experiments. d, Expression of TMEM9 in mouse tissues. Protein and mRNAs were extracted from six mouse tissues and assessed by IB and qRT-PCR. CRC cells served as a positive control. n = 3 independent experiments. e-g, Expression of TMEM9, CD44 and β -catenin in CRC TMA: IHC of TMEM9, CD44 and β -catenin was performed using TMA (Biomax, BC05023) (e), and H score (f) and Pearson's correlations (g) were calculated. n = 36 biologically independent samples. h, Co-expression of TMEM9 with AXIN2. Oncomine analysis of GSE20842, GSE5206 and TCGA data sets; 10% gene rank; P < 0.0001; fold change > 2; compared with normal cells. i,j, Co-expression of TMEM9 with Wnt/β -catenin target genes. GEO data sets (GDS2947) were analysed for each gene expression in normal intestine and matched CRC samples (32 patient samples, i). Pearson's correlations were determined (j). Scale bars, 20 μ m; NS, not significant. Error bars represent mean ± s.d. Two-sided unpaired t-test.
NATurE CEll BiOlOGy signalling in CRC, we examined whether TMEM9 is co-expressed with β -catenin and its target gene (CD44) 19 . IHC results showed the positive correlation between TMEM9 and both β -catenin and CD44 ( Fig. 1g ). Moreover, multiple gene expression data sets indicated the upregulation of both TMEM9 and AXIN2 in CRC ( Fig. 1h and Supplementary Table 1 ). Similarly, GDS2947 data sets in the Gene Expression Omnibus showed the significant upregulation and positive correlation of TMEM9 and Wnt signalling-associated genes (AXIN2, CD44, LGR5) in CRC, compared to adjacent normal samples ( Fig. 1i,j) . These results suggest that TMEM9 is highly expressed in CRC with hyperactivation of β -catenin and its target genes.
Activation of Wnt/β-catenin signalling by TMEM9 in vitro and in vivo.
To understand the pathologic impacts of TMEM9 upregulation to intestinal tumorigenesis, we examined the effects of TMEM9 depletion on CRC-related cellular signalling. HCT116 CRC cells stably expressing shRNAs against TMEM9 displayed the downregulation of Wnt signalling target genes (AXIN2, CD44), while other signalling pathways were barely affected ( Fig. 2a and Supplementary  Fig. 1a,b ). Conversely, ectopic expression of TMEM9 in IECs upregulated Wnt targets ( Fig. 2b , and Supplementary Fig. 1c ). These results imply that TMEM9 might be associated with Wnt/β -catenin signalling, which led us to hypothesize that TMEM9 positively modulates Wnt/β -catenin signalling. To test this, we analysed the effects of TMEM9 on the β -catenin protein. Immunofluorescent (IF) staining showed that TMEM9 expression increased both cytosolic and nuclear β -catenin ( Fig. 2c ). Consistently, TMEM9 overexpression increased the half-life of β -catenin protein ( Fig. 2d and Supplementary Fig. 1d ). Additionally, β -catenin reporter (TOPFLASH) and qRT-PCR assays showed that TMEM9 expression per se enhanced the transcriptional activity of β -catenin ( Fig. 2e and Supplementary Fig. 1e ,f). Intriguingly, TMEM9 increased the response of β -catenin reporter activation by LiCl, a GSK3 inhibitor ( Fig. 2f) . Similarly, TMEM9 also enhanced β -catenin protein stabilization induced by Wnt3a ( Fig. 2g ). Additionally, iCRT14, an inhibitor of β -catenin-TCF binding, suppressed TMEM9-activated luciferase activity ( Fig. 2h ). To complement gain-of-function assays, we also utilized shRNAs to deplete endogenous TMEM9 ( Supplementary Fig. 1g ). Based on the high expression of TMEM9 in CRC cell lines ( Fig. 1c,d ), we used CRC cells for knockdown experiments. TMEM9-depleted HCT116 cells displayed a decrease in β -catenin protein as well as active β -catenin ( Fig. 2i ). Next, we examined the effects of TMEM9 knockdown on β -catenin's transcriptional activity. qRT-PCR and β -catenin reporter assays showed that TMEM9 depletion downregulated AXIN2 and β -catenin reporter activity in CRC cells (Fig. 2j,k and Supplementary  Fig. 1h ,i). Of note, TMEM9 depletion-induced AXIN2 downregulation was rescued by ectopic expression of β -catenin ( Fig. 2l ), suggesting that β -catenin mediates the effect of TMEM9 on AXIN2 upregulation. Consistently, similar effects were observed in TMEM9 knockout (KO) HCT116 cells ( Fig. 2m and Supplementary Fig. 1j ,k). Next, to better understand the epistasis of TMEM9 in Wnt signalling, we assessed the effects of TMEM9 depletion on β -cateninmediated transactivation by Dvl2 and Wnt3a. We found that TMEM9 knockdown diminished both Dvl2-and Wnt3a-induced β -catenin reporter activation ( Fig. 2n ), implying that TMEM9 might activate Wnt signalling at the same or downstream level of Wnt ligands and Dvls. We also examined the in vivo effects of TMEM9 on Wnt signalling by axis duplication assays using Xenopus laevis embryos. Ectopic activation of Wnt/β -catenin signalling in ventrovegetal blastomeres generates a secondary anterior-posterior axis 20 (Fig. 2o ). We observed that ventro-vegetal microinjection of xTMEM9 or xβ-catenin (positive control) mRNA induced the additional anterior-posterior axis ( Fig. 2p-r) . These results suggest that TMEM9 activates Wnt signalling in vitro and in vivo.
TMEM9 binds and activates v-ATPase by promoting v-ATPase-ATP6AP2 assembly. To elucidate the molecular mechanism of TMEM9-activated Wnt/β -catenin signalling, we sought to identify TMEM9-interacting proteins using tandem affinity protein purification and mass spectrometry analysis (TAP-MS/MS) ( Fig. 3a) . Interestingly, we identified that TMEM9 was highly associated with the v-ATPase protein components ATP6AP2, a v-ATPase accessory protein, and ATP6V0D1, a rotary subunit mediating V0-V1 coupling 14 . ATP6AP2 has previously been shown to connect the LRP signalosome to v-ATPase 16 . Thus, we hypothesized that TMEM9 modulates v-ATPase activity through physical interaction with v-ATPase and ATP6AP2. Co-immunoprecipitation (co-IP) assays confirmed that TMEM9 bound to both ATP6AP2 and ATP6V0D1 in 293T (Fig. 3b ,c) and CRC cells ( Fig. 3d and Supplementary  Fig. 2a ). However, unlike the previous study 16 , TMEM9 did not bind to LRP signalosome components ( Fig. 3e ,f), consistent with our proteomic analysis ( Fig. 3a ). Based on TMEM9's SP and TMD, we also tested whether TMEM9's membrane targeting is required for interaction with either ATP6V0D1 or ATP6AP2. Co-IP for either wild-type (WT) or a Δ TMD mutant (MT) of TMEM9 showed that TMEM9's TMD is essential for interacting with ATP6AP2 ( Fig. 3g ), but not with ATP6V0D1 ( Fig. 3h ). ATP6V0D1 functions as a central stalk that regulates v-ATPase assembly 21 . Additionally, ATP6AP2 is indispensable for v-ATPase assembly 22 . Thus, modulating the interaction between ATP6AP2 and v-ATPase might affect the activity of v-ATPase. To test this, we asked whether TMEM9 promotes v-ATPase assembly. Co-IP assays showed that TMEM9 expression enhanced ATP6AP2-ATP6V0D1 interaction in 293T cells ( Fig. 3i ). Conversely, TMEM9 depletion decreased ATP6AP2-ATP6V0D1 binding in HCT116 cells ( Fig. 3j ). Next, we assessed the effects of TMEM9 on v-ATPase activity. We performed co-IP experiments using ATP6AP2 antibody in HeLa (Control vector (Vec) versus TMEM9 expressing) cells and quantified ATP6AP2associated ATPase activity by measuring inorganic phosphate (P i ) released by ATP hydrolysis. Co-immunoprecipitates of ATP6AP2 from HeLa-TMEM9 displayed a markedly increased level of P i following ATP addition, compared with those from control ( Fig. 3k ). These results suggest that TMEM9 positively modulates v-ATPase activity. Additionally, amino acid sequence analysis located a dimerization motif ([G/S/A/L/I]-XXX-[G/S/A/L/I]) 23 in the TMD of TMEM9 ( Fig. 3l ). Co-IP assays showed that different epitopetagged TMEM9 proteins bound to each other, implying the potential oligomerization of TMEM9 ( Supplementary Fig. 2b ). Also, binding domain-mapping analysis suggests that the N terminus of TMEM9 is required for binding to ATP6AP2 ( Fig. 3m ).
TMEM9 contains an SP and one α -helix TMD (Fig. 1a ), implying its possible localization to membranous organelles and/or the plasma membrane. IF staining showed that both endogenous and exogenous TMEM9 localized to the cytoplasm and the perinucleus with a speckled pattern in HCT116 and HeLa cells ( Fig. 3n and Supplementary Fig. 2c ), consistent with the results from CRC tissue immunostaining (Fig. 1e ). Co-IF showed that TMEM9 mainly co-localized with LAMP1, a marker for the MVB (Fig. 3o ). The lower pH in the lumen of membranous organelles is maintained by v-ATPase-mediated proton efflux. Given the subcellular localization of TMEM9 in the MVB ( Fig. 3o ) and TMEM9-activated v-ATPase ( Fig. 3k ), we tested whether TMEM9 increases intracellular vesicle acidification, using Lysotracker, a marker for acidic organelles. Depletion of TMEM9 significantly decreased vesicle acidification ( Fig. 3p and Supplementary Fig. 2d ), while TMEM9 expression increased it ( Fig. 3q and Supplementary Fig. 2e ). To validate the effects of TMEM9 on vesicular acidification, we utilized bafilomycin A1 (BAF), an inhibitor of v-ATPase 24 . BAF inhibited TMEM9induced vesicular acidification (Fig. 3q ). These results suggest that TMEM9 binds to ATP6AP2 and v-ATPase, and increases v-ATPase activity, which results in the vesicular acidification ( Fig. 3r ). ATP1A1  ATP1A2  ATP1B1  ATP1B3  ATP2A1  ATP2A2  ATP5C1  ATP5A1  ATP5B  ATP6AP2  ATP6V0D1  RAB1A  RAB10  IPO4, 8, 
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Activation of Wnt/β-catenin signalling by TMEM9-v-ATPasemediated APC degradation. We next questioned whether v-ATPase is required for TMEM9-induced Wnt signalling activation. Recent studies have proposed a crucial role of MVBs in transducing Wnt signalling 3, 16 . Given (1) the localization of TMEM9 to MVBs ( Fig. 3o ), (2) co-expression of TMEM9 with β -catenin target genes in CRC ( Fig. 1e -j), (3) TMEM9-activated Wnt/β -catenin signalling ( Fig. 2) and (4) TMEM9-enhanced v-ATPase activity ( Fig. 3 ), we hypothesized that TMEM9-induced vesicular acidification activates Wnt/β -catenin signalling. We found that blockade of v-ATPase using BAF suppressed TMEM9-induced β -catenin protein stabilization ( Supplementary Fig. 3a,b) . Additionally, TMEM9-activated β -catenin reporter was suppressed by BAF or concanamycin A (CMA), another v-ATPase inhibitor 24 (Fig. 4a) . Additionally, Δ TMD-TMEM9 was unable to activate β -catenin reporter activity (Fig. 4b,c and Supplementary Fig. 3c,d) , indicating that TMEM9's membrane targeting is necessary for Wnt signalling activation. We also observed that ATP6AP2 depletion inhibited TMEM9-induced Wnt signalling activation ( Supplementary Fig. 3e,f ), suggesting that ATP6AP2 is required for TMEM9-activated Wnt signalling. We further tested whether TMEM9 and ATP6AP2 are reciprocally dependent in activating Wnt signalling. TMEM9 depletion-reduced Wnt/β -catenin signalling activity was not restored by ATP6AP2 and vice versa (Fig. 4d,e and Supplementary Fig. 3g,h) , unlike β -catenin, a positive control ( Supplementary Fig. 3i,j) . MVB acidification activates FZD/LRP6-dependent Wnt/β -catenin signalling 16 . Thus, we tested whether TMEM9 affects FZD/ LRP6-mediated Wnt signalling activation. We found that TMEM9activated Wnt/β -catenin signalling was not affected by Dkk-1, a Wnt antagonist ( Fig. 4f and Supplementary Fig. 3k ). Moreover, TMEM9 depletion inhibited Wnt/β -catenin signalling, independently of Wnt3a ( Fig. 4g and Supplementary Fig. 3l ). Although it was proposed that MVB increases the secretion of Wnt ligands 25, 26 , TMEM9depletion-downregulated Wnt/β -catenin signalling was not affected by porcupine inhibitor, IWP-2 ( Fig. 4h and Supplementary Fig. 3m ).
It was recently shown that mutant APC still induces β -catenin degradation 10 . Having determined that TMEM9 depletion inhibits Wnt/β -catenin signalling regardless of APC mutation (Fig. 2j,k and Supplementary Fig. 1h ,i), we tested whether TMEM9-induced MVB acidification alters APC protein level. Interestingly, TMEM9 KO and shTMEM9 cells showed an increase in APC protein ( Fig. 4i and Supplementary Fig. 3n ). v-ATPase inhibitors also increased APC protein with decreased β -catenin in both HCT116 (APC WT; 2,843 amino acids) and HT29 (APC MT; 1,555 amino acids) 10, 27 cells, while hydroxychloroquine (HCQ), an inhibitor of autophagy, did not (Fig. 4j ). Vesicular acidification is indispensable for lysosomal protein degradation 28 . Thus, we determined whether lysosomal protein degradation mediates TMEM9-depletion-increased APC protein. We found that inhibition of cathepsin, a lysosomal protease, increased both WT and MT APC protein along with the decreased β -catenin ( Fig. 4k ). Next, we asked whether APC mediates TMEM9-depletion-induced β -catenin downregulation using APC KO cells. shTMEM9 showed no decrease in β -catenin protein and AXIN2 expression in APC KO-HCT116 and -HT29 cells ( Fig. 4l-o) . We also found that β -catenin bound to both WT and MT APC, which was increased by TMEM9 KO (Fig. 4p-s) . Similarly, BAF also increased the APC-β -catenin interaction (Fig. 4r,s) . These results suggest that the TMEM9-v-ATPase axis activates Wnt/ β -catenin signalling by lysosomal degradation of APC.
Transactivation of TMEM9 by β-catenin. Next, we sought to understand how TMEM9 is upregulated in CRC. Having observed the co-expression of TMEM9 with β -catenin targets in CRC ( Fig. 1e-j) , we tested whether Wnt/β -catenin signalling upregulates TMEM9 in CRC. Interestingly, iCRT14-treated HCT116 exhibited downregulation of TMEM9 transcripts (Fig. 5a ) and protein (Fig. 5b) .
Similarly, Engrailed-∆ N-LEF1 (Eng-LEF1), a dominant-negative MT for β -catenin-mediated transcription 29 , also downregulated TMEM9 (Fig. 5c ). Conversely, Wnt3a upregulated TMEM9 in 293T cells (Fig. 5d ). Additionally, β -catenin ectopic expression upregulated TMEM9 (Fig. 5e,f) , which was inhibited by Eng-LEF1 (Fig. 5f ). In silico analysis identified the potential TCF/LEFs binding elements (TBEs; CTTTGA/TA/T) in conserved non-coding sequences (CNSs) between human and mouse TMEM9 promoter ( Fig. 5g) , which led us to test whether β -catenin directly transactivates TMEM9, using chromatin immunoprecipitation (ChIP) assays. ChIP for endogenous β -catenin showed that β -catenin occupied the proximal promoter of TMEM9 in HCT116 cells (Fig. 5h) . Given that TMEM9 is upregulated by Wnt signalling activation ( Fig. 5d-f ), we also asked whether β -catenin conditionally occupies the TMEM9 promoter following Wnt signalling activation. Indeed, in the setting of treatment of LiCl, β -catenin occupied the TMEM9 promoter ( Fig. 5i ). Next, we examined whether β -catenin upregulates TMEM9 in vivo. Both TMEM9 mRNA and protein levels were highly increased in intestinal adenomas of APC MIN mice (Fig. 5j,k) . These results suggest that β -catenin directly transactivates TMEM9 in CRC.
Suppression of intestinal tumorigenesis by TMEM9 blockade.
Our results showed (1) specific upregulation of TMEM9 in CRC and (2) TMEM9-activated Wnt/β -catenin signalling. Moreover, the Kaplan-Meier plot of human CRC showed lower survival with high expression of TMEM9 ( Supplementary Fig. 4a ). These data prompted us to hypothesize that TMEM9 plays key roles in intestinal tumorigenesis. To test this, we assessed the effects of TMEM9 depletion on CRC cell proliferation (shCtrl versus shTMEM9). We found that TMEM9-depleted CRC cells displayed decreased cell growth (Fig. 6a-c and Supplementary Fig. 4b ,c) without a change in cell death (Fig. 6d) , which was rescued by β -catenin expression ( Fig. 6e) . These results suggest that β -catenin mediates TMEM9's mitogenic effect on CRC cells.
To gain further insights into the tumorigenic roles of TMEM9 in more physiological settings, we subcutaneously injected TMEM9depleted CRC cells into immunocompromised mice and analysed for tumour formation. TMEM9-depleted CRC cells developed smaller tumours (Fig. 6f,g and Supplementary Fig. 4d,e ) with decreased cell proliferation (Ki67) and downregulated CD44 ( Supplementary Fig. 4f ).
To complement the ex vivo results, we established TMEM9 KO mice ( Fig. 6h and Supplementary Fig. 4g ). TMEM9 KO mice were viable without any apparent phenotype (Fig. 6i,j and Supplementary  Fig. 4h ). To determine whether TMEM9 KO suppresses intestinal tumorigenesis, we generated APC MIN :TMEM9 −/− compound strains. APC MIN mice die with multiple adenomas in the small intestine 30 . While the median survival of APC MIN mice was 124 days of age, that of APC MIN :TMEM9 −/− mice was 323 days. Of note, heterozygous KO of TMEM9 (APC MIN :TMEM9 ± ) was also sufficient to increase survival (median survival: 199 days; Fig. 6i and Supplementary Fig. 4i ). We also monitored the tumour size and number of APC MIN -, APC MIN :TMEM9 ± -and APC MIN :TMEM9 −/− -induced tumours at three months of age. Although TMEM9 KO slightly decreased tumour size (Fig. 6k ), tumour number was significantly reduced compared to TMEM9 WT (Fig. 6l ). qRT-PCR and IHC analyses showed a decreased transcriptional activity ( Fig. 6m ) and protein level of β -catenin ( Fig. 6n,o) , diminished β -catenin target expression (cyclin D1, CD44; Fig. 6n and Supplementary Fig. 4j ) and reduced cell proliferation (Fig. 6q,r) , compared to APC MIN mice. Of note, the number of nuclear β -catenin-positive cells in tumours was decreased in APC MIN :TMEM9 −/− mice (Fig. 6o,p) without a significant difference in apoptosis (c-Cas3; Supplementary Fig. 4k ) and epithelial-mesenchymal transition (EMT; Supplementary  Fig. 4l,m) . These results strongly suggest that genetic ablation of TMEM9 suppresses intestinal tumorigenesis ex vivo and in vivo. 
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Inhibition of intestinal tumorigenesis by v-ATPase inhibitors.
Having determined that TMEM9 activates Wnt/β -catenin signalling via v-ATPase, we next asked whether v-ATPase inhibitors suppress intestinal tumorigenesis. First, we assessed the impacts of v-ATPase inhibitors on CRC cell growth. BAF and CMA significantly inhibited CRC cell proliferation (HT29, HCT116; Fig. 7a ). Of note, the impact of v-ATPase inhibitors on CRC cell growth suppression was diminished in TMEM9 KO CRC cells (Fig. 7b ) compared to TMEM9 WT cells (Fig. 7a ). We also examined the effect of v-ATPase inhibitors on CRC using the APC MIN mouse model. While the normal intestinal homeostasis was not affected by v-ATPase inhibitors, APC MIN mice treated with BAF or CMA exhibited a decrease in intestinal adenoma number, β -catenin, β -catenin targets and tumour cell proliferation (Fig. 7c-h and Supplementary Fig. 5a,b ) compared to vehicle-treated control mice. Similarly, intestinal tumour organoids treated with v-ATPase inhibitors also showed decreased tumour growth, whereas normal crypt organoids exhibited no impairment in growth and expansion (Fig. 7i,j) . These results led us to further test the impacts of v-ATPase inhibitors on human CRC, employing patient-derived xenograft (PDX) models. Similar to the mouse results, BAF decreased 
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PDX growth (Fig. 8a,b and Supplementary Fig. 6a,b) , with reduced β -catenin and target expression ( Fig. 8c ) and cell proliferation (Ki67, pHH3; Fig. 8d,e and Supplementary Fig. 6c ). Additionally, BAFtreated PDXs exhibited an increase of APC and decrease in nuclear β -catenin ( Supplementary Fig. 6d,e ). These results strongly suggest that the blockade of v-ATPase suppresses intestinal tumorigenesis with reduced Wnt/β -catenin signalling activity.
Discussion
Several regulatory mechanisms of v-ATPase activity have been proposed. For instance, v-ATPase assembly is reversible 31, 32 and controlled by E3 ligase 33 . TMEM9 is mainly localized in the MVBs and interacts with several components of the proton pump and their accessory proteins, ATP6AP2 and v-ATPase. We found that TMEM9 increases the ATP6AP2-ATP6V0D1 interaction. Given (1) the interaction of TMEM9 with both ATP6AP2 and ATP6V0D1 and (2) the relatively small size of TMEM9 (186 amino acids), it is likely that TMEM9 acts as a molecular adaptor modulating the interaction between ATP6AP2 and ATP6V0D1. Unlike TMEM9, other v-ATPase components (ATP6AP2, ATP6V0D1, TMEM9B (a homologous gene of TMEM9)) are not upregulated in human CRC ( Supplementary Fig. 2f ). Thus, 
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NATurE CEll BiOlOGy hyperactivation of v-ATPase in CRC might be mainly due to upregulation of TMEM9. It has been shown previously that ATP6AP2 binds to LRPs and Fzd to promote Wnt signals 16 . However, our mass spectrometry and co-IP results did not detect LRP signalosome components as TMEM9-interacting proteins (Fig. 3a ,e,f), implying that TMEM9-activated Wnt signalling in CRC might be somewhat distinct from ATP6AP2-LRP-Fzdmediated Wnt signalling activation. Despite frequent mutations in APC (~70%) 2 , accumulating evidence suggests that additional intrinsic and extrinsic factors may further hyperactivate Wnt signalling during tumour initiation and metastasis [9] [10] [11] 34 . It has also been shown that mutant APC still negatively modulates β -catenin 10 . Intriguingly, TMEM9 activates Wnt/β -catenin signalling regardless of APC mutation status ( Fig. 2j and Supplementary Fig. 1h,i) . While β -catenin is degraded by β -TrCP-mediated ubiquitination, both MT and WT APC are under lysosomal degradation induced by TMEM9-v-ATPase-activated vesicular acidification ( Fig. 4i-k ), suggesting the alternative mechanism of Wnt signalling hyperactivation in CRC. It is also noteworthy that TMEM9 is transactivated by β -catenin, suggesting that TMEM9 might function as an amplifier of Wnt signalling in CRC.
TMEM9 KO mice are viable without any discernible phenotype, which might be due to the relatively low expression of TMEM9 in normal tissues. Given the upregulation of TMEM9 in CRC cells and its pivotal role in CRC cell proliferation, molecular targeting of the TMEM9-v-ATPase axis might provide a potential benefit in CRC treatment, with minimal detrimental effects to normal cells. Indeed, v-ATPase inhibitors displayed strong tumour suppressive effects on CRC suppression in cell lines, organoids, mice and human PDXs, without damage to normal tissues ( Figs. 7 and 8) .
Together, our results reveal an unexpected positive feedback mechanism of Wnt signalling by TMEM9, a regulator of v-ATPase, and propose that the blockade of TMEM9-v-ATPase might be a viable option for TMEM9-expressing CRC treatment.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41556-018-0219-8.
nature research | reporting summary
April 2018
Corresponding author(s): Jae-Il Park
Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
No software was used for data collection.
Data analysis
The human IPI databases version 3.6 (determination of peptide sequences) and SEQUEST ver.28 (fragmentation patterning) are used for analysis of mass spectrometry result. All statistical analyses and plots were generated using Graphpad Prism 7. Correlation analysis and heatmap were generated with the Graphpad Prism 7. Correlation analysis was conducted in Exel. Images were analyzed using AxioVision, ImageJ, and Zen software.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
